MedTrace Logo

COVID-19 Convalescent Plasma Therapy

NCT04747158 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2021-03-02

No results posted yet for this study

Summary

This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 \[COVID-19\] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).

Conditions

Interventions

BIOLOGICAL

Convalescent plasma

COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2

Sponsors & Collaborators

  • Consejo Nacional de Ciencias y Tecnología, Paraguay

    collaborator UNKNOWN

  • Ministerio de Salud Pública y Bienestar Social, Paraguay

    collaborator UNKNOWN

  • Centro de información y recursos para el desarrollo, Paraguay

    collaborator UNKNOWN

  • Universidad Nacional de Asunción

    lead OTHER

Principal Investigators

  • Angelica Jimenez de Samudio, MD,MSc · Facultad de Ciencias Médicas - Universidad Nacional de Asunción

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2020-12-10
Completion
2021-01-10

Countries

  • Paraguay

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04747158 on ClinicalTrials.gov